![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Risk of tuberculosis after initiation of
antiretroviral therapy among people
living with HIV in Europe
|
|
|
Glasgow 2022 Oct 23-26
IS. Johansen, A. Roen, RM. Iguacel, J Nemeth, L. Fenner, R. Zangerle, R. Paredes, M. Lipman, R. Miller, I. Suarez, S. De Wit, F. Wit, C. Mussini, A. Saracino, E. Fontas, D. Canetti, N. Chkhartishvili, H. Knobel, X. Xu, S. Schlabe, M. Law, N. Wetzstein, A. Volny Anne, N. Jaschinski, B. Neesgaard, L. Ryom, L. Peters, H. Garges, J.Rooney, C. Kraef, D. Podlekareva, A. Mocroft, O. Kirk, on behalf of the RESPOND Study group
![1117221](../images/111722/111722-16/1117221.gif)
![1117222](../images/111722/111722-16/1117222.gif)
![1117223](../images/111722/111722-16/1117223.gif)
![1117224](../images/111722/111722-16/1117224.gif)
![1117225](../images/111722/111722-16/1117225.gif)
![1117226](../images/111722/111722-16/1117226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|